丰明乾 - 华中农业大学 - 生物医学与健康学院

个人简介

教育经历 1993.9-1997.7 西北农林科技大学作物遗传育种农学学士学位 1997.9-2000.7 西北农林科技大学生物化学与分子生物学理学硕士学位 2005.9-2008.7 南京大学生物学理学博士学位科研与学术工作经历 2000.7-2005.9 华中农业大学生命科学技术学院讲师 2008.10-2015.11 美国NIH，博士后，助理研究员（Research Fellow） 2011.12至今，华中农业大学教授

研究领域

抗体工程，肿瘤免疫学，病毒免疫学

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Immunotoxin targeting glypican-3 regresses liver cancervia dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015, 6:6536 2. Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Nat Sci Acad USA. 2013, 110: E1083-91. 3. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014, 588:377-82. 4. Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60:576-87 5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, and Ho M. A human single-domain antibody elicits potent anti-tumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther, 2013, 12: 416-26. 6. Feng M., Kim H., Phung Y., and Ho M. Recombinant soluble glypican3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer, 2011, 128:2246-2247. 7. Feng M., Zhang J., Anver M, Hassan R., and Ho M. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer, 2011, 2: 123-131. 8. Ho M., Feng M., Fisher R.J., Rader C., and Pastan I. A novel high affinity human monoclonal antibody to mesothelin. Int J Cancer., 2011, 128: 2020-2030. 9. Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, and Ho M. HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer, 2011, 2:280-91. 10. Xiang X., Phung Y., Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., FitzGerald D., and Ho M. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. Plos one, 2011, 6: e14640. 11. Yu L., Feng M., Kim H., Phung Y., Kleiner D.E., Gores G..J., Qian M., Wang X.W., and Ho M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer,2010, 1:141-149.